What's Happening?
Setara Biosciences has officially launched with $90 million in Series A funding. This new biotech company was formed to advance a portfolio of small molecule precision medicine programs for rare diseases, which were spun out from Jazz Pharmaceuticals.
Jazz Pharmaceuticals had acquired Actio Biosciences earlier this year, and as part of that deal, committed to spinning out Actio's remaining assets while retaining a stake in the new venture. David Goldstein, founder of Actio, will lead Setara Biosciences as its president and executive officer. The lead asset for Setara will be STAR-0871, a TRPV4 inhibitor previously known as ABS-0871, which is being developed for Charcot-Marie-Tooth disease type 2C (CMT2C) and overactive bladder. STAR-0871 has already completed a Phase 1 trial in healthy volunteers and holds rare pediatric disease, orphan drug, and fast track designations from the FDA. A Phase 1b study for CMT2C is slated to begin in 2027, alongside a Phase 2a study for overactive bladder.
Why It's Important?
The launch of Setara Biosciences with substantial funding highlights a strategic trend in the pharmaceutical industry where larger companies acquire promising biotechs for their lead programs and then spin off other valuable assets. This approach allows Jazz Pharmaceuticals to focus on its primary acquisition, ABS-1230 for KCNT1-related epilepsy, while ensuring the continued development of other potential therapies. For patients with rare diseases like CMT2C, this means continued investment and progress towards new treatment options, particularly for conditions with limited therapeutic alternatives. The FDA's designations for STAR-0871 underscore the urgent medical need and potential for expedited development. Furthermore, the company's ambition to explore broader applications for STAR-0871, such as overactive bladder, could significantly expand its market potential and impact a larger patient population, demonstrating a strategic move to maximize the value of its pipeline beyond initial rare disease indications.
What's Next?
Setara Biosciences plans to initiate a Phase 1b study for STAR-0871 in patients with Charcot-Marie-Tooth disease type 2C (CMT2C) in 2027. Concurrently, a Phase 2a study for STAR-0871 in overactive bladder will also commence. The company will continue to develop earlier-stage programs acquired from Actio Biosciences, focusing on genetic epilepsies and potential expansion indications like migraine. The Series A funding, led by investors such as Deerfield Management, Canaan, Droia Ventures, EcoR1, Euclidean Capital, Regeneron Ventures, and Jazz Pharmaceuticals itself, provides the capital necessary to advance these clinical trials and research efforts. Future developments will likely include further clinical trial results, potential regulatory milestones, and continued exploration of STAR-0871's efficacy across various conditions, potentially leading to additional funding rounds or partnerships as the pipeline progresses.
Beyond the Headlines
This development reflects a growing sophistication in biotech financing and corporate strategy, where asset spin-offs are used to optimize R&D focus and capital allocation. It also underscores the increasing importance of precision medicine in addressing rare diseases, leveraging genetic insights to develop targeted therapies. The involvement of multiple venture capital firms, alongside Jazz Pharmaceuticals, indicates strong investor confidence in the potential of these rare disease assets and the leadership of David Goldstein. The strategy of pursuing both rare and more common indications for the same drug, as seen with STAR-0871, represents a pragmatic approach to drug development, potentially accelerating market access and generating broader revenue streams. This model could become more prevalent as pharmaceutical companies seek to de-risk their pipelines and maximize the value of their intellectual property.
